In order to generate therapeutic peptides, Anergix transduces fibroblasts with a gene designed to encode and secrete the efficacious peptide. These cells are sequestered within an implant and administered subcutaneously, in order to protect them from the immune response of the recipient and to allow removal in the event of an adverse reaction. Cells can survive for several months in vivo and provide a constant dosage of peptide.